抗白细胞介素6及其受体单克隆抗体治疗自身免疫病研究进展

Research progress in autoimmune disease treatment with monocional antibodies against interleukin-6 and its receptor

白细胞介素6（interleukiw-6，IL-6）是调节免疫反应和炎性反应的多效性细胞因子，通过形成IL-6／IL-6受体（1176receptor，IL-6R）／gp130复合体发挥生物学作用。因此，靶向抑制IL-66或IL-6R的单克隆抗体（单抗）可以用来治疗自身免疫病。随着包括IL-6／IL-6R抑制剂在内的多种生物制剂推向临床，新的问题也开始产生，如选用何种药物既可以改善病情又能避免严重不良反应。此文以抗II，6单抗Sirukumab和抗IL-6R单抗Tocilizumab为代表，着重对这类药物治疗各种自身免疫病的有效性和安全性进行综述。

Interleukin-6 （IL-6） is a cytokine with a broad spectrum of effects on immune and inflammatory responses, whose biological function is transduced by the ID6/interleukin 6 receptor （IL-6R）/gp130 complex. Monoclonal antibodies （mAb） targeting IL6 or IL-6R can block signal transduction and therefore alleviate severity of autoimmune diseases. With varieties of biological agents including IL-6/IL-6R blockades becoming clinically available, new problems, such as which agent should be chosen to improve disease outcome and avoid severe adverse reaction, also arise. This review, focusing on Sirukumab （anti-II.-6 mAb） and Tocilizumab （anti-IL-6R mAb） as representative agents, discusses the efficacy and safety of anti-IL-6/IL-6R mAb as treatment for autoimmune diseases.